These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9792136)

  • 21. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study.
    Buck AC; Cox R; Rees RW; Ebeling L; John A
    Br J Urol; 1990 Oct; 66(4):398-404. PubMed ID: 1699628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phytotherapeutic Agents for Benign Prostatic Hyperplasia: An Overview.
    Sharma M; Chadha R; Dhingra N
    Mini Rev Med Chem; 2017; 17(14):1346-1363. PubMed ID: 27337973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens.
    Levin RM; Das AK
    Urol Res; 2000 Jun; 28(3):201-9. PubMed ID: 10929430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effects of mepartricin on the symptomatology of prostatic hypertrophy--double-blind controlled trial].
    Vanden Bossche M; Abi Aad A; Vandendris M; Van Cangh P; Schulman C
    Acta Urol Belg; 1991; 59(1):93-104. PubMed ID: 1718154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Medical treatment of the prostatism syndrome. Comparative study].
    Martínez Agulló E; Gallego Gómez J; Jiménez Cruz FJ
    Arch Esp Urol; 1987 May; 40(4):247-53. PubMed ID: 2443084
    [No Abstract]   [Full Text] [Related]  

  • 26. An overview of phytotherapeutic approaches for the treatment of benign prostatic hyperplasia.
    Aggarwal S; Verma A; Shukla R; Batra S; Bhardwaj TR; Kumar M
    Mini Rev Med Chem; 2014; 14(3):257-70. PubMed ID: 24456273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phytotherapy in the management of benign prostatic hyperplasia.
    Lowe FC
    Urology; 2001 Dec; 58(6 Suppl 1):71-6; discussion 76-7. PubMed ID: 11750257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mepartricin in BPH. A new dosage approach].
    Prezioso D; Fabrizio F; Russo A; Lotti T
    Minerva Urol Nefrol; 1996 Jun; 48(2):117-20. PubMed ID: 8815556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo].
    Tasca A; Barulli M; Cavazzana A; Zattoni F; Artibani W; Pagano F
    Minerva Urol Nefrol; 1985; 37(1):87-91. PubMed ID: 2413558
    [No Abstract]   [Full Text] [Related]  

  • 30. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
    Klippel KF; Hiltl DM; Schipp B
    Br J Urol; 1997 Sep; 80(3):427-32. PubMed ID: 9313662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
    Boyle P; Robertson C; Lowe F; Roehrborn C
    BJU Int; 2004 Apr; 93(6):751-6. PubMed ID: 15049985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: a phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy.
    Kaplan SA
    J Urol; 2014 Jul; 192(1):164. PubMed ID: 25629105
    [No Abstract]   [Full Text] [Related]  

  • 33. [Mepartricin 150.000 (40 mg) vs mepartricin 50.000 U (13 mg) in the treatment of BIP. Double blind clinical trial].
    Mirone V; Prezioso D; Palmieri A; Lotti T
    Minerva Med; 1996 Apr; 87(4):147-54. PubMed ID: 8700338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial.
    Sengupta G; Hazra A; Kundu A; Ghosh A
    Clin Ther; 2011 Dec; 33(12):1943-52. PubMed ID: 22177370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What do we know about phytotherapy of benign prostatic hyperplasia?
    Allkanjari O; Vitalone A
    Life Sci; 2015 Apr; 126():42-56. PubMed ID: 25703069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phytotherapy for Benign Prostatic Hyperplasia.
    Keehn A; Taylor J; Lowe FC
    Curr Urol Rep; 2016 Jul; 17(7):53. PubMed ID: 27180172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacologic treatment of benign prostatic hypertrophy (BPH): a combination of mepartricin and simvastatin. Analysis and results].
    Marino G; Pugno E; Cevoli R; Griffa D; Pastorini S; Cocimano V
    Minerva Urol Nefrol; 1991; 43(4):279-82. PubMed ID: 1725937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia.
    Yasumoto R; Kawanishi H; Tsujino T; Tsujita M; Nishisaka N; Horii A; Kishimoto T
    Clin Ther; 1995; 17(1):82-7. PubMed ID: 7538904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.